BlossomHill Therapeutics to present BH-30236 clinical data at ASH meeting
BLSM•BlossomHill Therapeutics will present preclinical and clinical data on BH-30236 at the American Society of Hematology annual meeting on December 14, 2026.
1. Data presentation
BlossomHill Therapeutics will present preclinical and clinical data on BH-30236 at the American Society of Hematology annual meeting on December 14, 2026. The findings support the oral CLK inhibitor’s mechanism of action, with consistent biological effects across preclinical studies and clinical testing. BH-30236 is in a Phase 1/1b trial for adults with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndrome.
